McKesson (MCK) Declares Quarterly Dividend, Is The Stock Still Undervalued?
McKesson (MCK) recently declared a quarterly dividend of US$0.94 per share, payable on October 1, 2026, with the ex dividend and record dates set for September 1, 2026. Investors may now reassess the stock’s income profile.
See our latest analysis for McKesson.
At a share price of US$856.19, McKesson’s recent 30 day share price return of 11.47% and 1 year total shareholder return of 23.02% indicate strengthening momentum ahead of the upcoming earnings report and this dividend.
If this kind of steady healthcare story appeals to you, it can be useful to look at other companies in similar areas using a focused screener such as 41 healthcare AI stocks
McKesson appears to be a solid healthcare operator with broad reach and rising earnings expectations. However, the share price has already moved sharply over the past month. Is the stock still reasonably priced for new money heading in?
Most Popular Narrative: 9.1% Undervalued
McKesson’s most followed narrative places fair value at $941.40, which sits above the last close of $856.19 and frames the current share price debate.
Increasing adoption of specialty and oncology pharmaceuticals, alongside recent acquisitions (Core Ventures and PRISM Vision) that expand the provider network and service portfolio, are improving revenue mix quality and positioning the company for higher operating margins and earnings growth.
Want to understand why this narrative still supports a higher price than today? It focuses on steady top line expansion, firm margins and a richer earnings multiple that is tied to those forecasts rather than past results.
Result: Fair Value of $941.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to weigh policy pressure on drug pricing and the risk that vertically integrated players remove wholesalers like McKesson from parts of the supply chain.
Find out about the key risks to this McKesson narrative.
Next Steps
If this mixed picture on McKesson leaves you uncertain, act quickly. Review the underlying data, then weigh up the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond McKesson?
If McKesson has sharpened your focus on finding strong opportunities, do not stop here. Broaden your watchlist now so you are not chasing the crowd later.
- Spot potential value early by scanning companies that look mispriced on quality and fundamentals through the 55 high quality undervalued stocks.
- Strengthen your portfolio’s foundation by filtering for businesses with healthier finances using the solid balance sheet and fundamentals stocks screener (45 results).
- Get ahead of the market by hunting for lesser known quality stocks with the screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com